Stifel analyst Alex Thompson raised the firm’s price target on Spyre Therapeutics (SYRE) to $36 from $27 and keeps a Buy rating on the shares following recent positive Phase 1 data from Viridian Therapeutics’ (VRDN) VRDN-003 and GSK‘s (GSK) acquisition of Aiolos Bio for $1B upfront and $400M in milestones to gain their extended half-life TSLP antibody. The firm views both of these developments as further validation of the underlying half-life extension hypotheses of Apogee Therapeutics (APGE) and Spyre, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SYRE:
- Spyre Therapeutics files to sell 12M shares of common stock for holders
- Spyre Therapeutics initiated with a Buy at BTIG
- Spyre Therapeutics price target raised to $27 from $23 at Stifel
- Spyre Therapeutics initiated with bullish view at Jefferies, here’s why
- Nike upgraded, Paramount downgraded: Wall Street’s top analyst calls